Phase II Trial of Pyrazoloacridine (PZA) in Previously Untreated Hepatocellular Carcinoma (HCC) Patients.

Trial Profile

Phase II Trial of Pyrazoloacridine (PZA) in Previously Untreated Hepatocellular Carcinoma (HCC) Patients.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 20 Feb 2012

At a glance

  • Drugs PD 115934 (Primary)
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Sep 2010 Status changed from completed to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 05 Nov 2007 Status changed from in progress to completed.
    • 15 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top